ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix

Article content material

ObsEva Announce s
Relationship
with Syneos Well being to Commercialize Linzagolix

-Linzagolix, an oral GnRH antagonist, is pending regulatory approval within the U.S. and Europe for the remedy of uterine fibroids-

– Financing settlement with JGB Administration
to fund the deliberate launch of linzagolix in addition to different improvement and operational expense s –

–
Modification of Kissei unique license and provide settlement –

Advert hoc announcement pursuant to Artwork. 53 LR of the SIX Swiss Alternate

Article content material

GENEVA, Switzerland , October 1 3 , 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical firm devoted to bettering girls’s reproductive well being immediately introduced a strategic relationship with Syneos Well being® (Nasdaq:SYHN), the one totally built-in biopharmaceutical options group, to commercialize linzagolix.

Linzagolix has the potential to be a best-in-class GnRH receptor antagonist for the remedy of uterine fibroids because of its efficacy and favorable tolerability profile. ^1,2,3 If permitted, it could be the one GnRH antagonist for uterine fibroids with distinctive and versatile dosing choices, in addition to the primary to supply a low dose possibility to handle the wants of girls who can not or don’t wish to take hormones. ^1,4 Linzagolix can be being evaluated in an ongoing Section 3 (EDELWEISS 3) examine as a possible remedy for endometriosis-associated ache.

Article content material

Brian O’Callaghan, CEO of ObsEva, commented, “We’re thrilled to work with Syneos Well being on the commercialization of linzagolix. With a number one girls’s well being gross sales pressure, Syneos Well being is uniquely suited to assist our objective of providing aid to girls affected by uterine fibroids. Whereas conventional partnering preparations with massive pharma firms have been thought of, we consider that Syneos Well being affords ObsEva the most suitable choice to maximise and keep management, worth and optionality for this necessary product.   This Syneos Well being relationship, along with the newly introduced financing facility and revised Kissei license phrases, supplies ObsEva with a robust basis to execute on its commercialization plans.”

Article content material

“We’re proud to work with ObsEva on the event of a essential remedy that has the potential to alter the lives of girls affected by uterine fibroids,” mentioned Michelle Keefe, President, Industrial Options at Syneos Well being. “We’re excited to assist ObsEva of their launch using our full-service industrial mannequin together with company, discipline crew, and operations assist for linzagolix in each the U.S. and Europe.”

JGB Financing Settlement
ObsEva has additionally entered right into a convertible observe financing settlement with sure funds and accounts managed by JGB Administration, Inc. which is structured to supply as much as $135 million in borrowing capability, out there in 9 tranches. The primary tranche, for an preliminary $30 million, was funded at closing and used to retire the prevailing debt facility with Oxford Finance LLC. Notes issued in reference to every tranche can have a three-year time period. All principal and curiosity might be convertible into ObsEva’s frequent shares at a value of $3.20 per share.   In reference to every tranche, ObsEva will even difficulty warrants to buy its frequent shares, together with a warrant to buy 1,634,877 frequent shares that was issued on the preliminary closing. The warrants can have an train value of $3.67 per share and a 4 12 months time period from the date of issuance. Additional info with respect to the debt facility might be offered in a Kind 6-Okay filed by ObsEva with the Securities and Alternate Fee on October 13, 2021. Canaccord Genuity LLC acted as unique placement agent and monetary advisor to ObsEva.

Article content material

Kissei License and Provide Settlement
Lastly, ObsEva’s unique license and provide settlement with Kissei for linzagolix has been amended in order that first industrial gross sales milestones for the EU and the US will now be prolonged over a 5-year interval. As well as, North American royalty funds have been lowered to tiered single digit royalties on internet gross sales plus a provide value for the lively pharmaceutical ingredient (API).

About Linzagolix
Linzagolix is a novel, as soon as every day, oral GnRH receptor antagonist with a probably best-in-class profile ^1,2,3 . Linzagolix has accomplished medical trial improvement for the remedy of heavy menstrual bleeding related to uterine fibroids and is at the moment in late-stage medical improvement for the remedy of ache related to endometriosis. ObsEva licensed linzagolix from Kissei in late 2015 and retains worldwide industrial rights, excluding Asia, for the product. Linzagolix is just not at the moment permitted wherever on the earth.

Article content material

About ObsEva
ObsEva is a biopharmaceutical firm growing and commercializing novel therapies to enhance girls’s reproductive well being and being pregnant. Via strategic in-licensing and disciplined drug improvement, ObsEva has established a late-stage medical pipeline with improvement packages centered on new therapies for the remedy of uterine fibroids, endometriosis, and preterm labor. ObsEva is listed on the Nasdaq International Choose Market and is traded beneath the ticker image “OBSV” and on the SIX Swiss Alternate the place it’s traded beneath the ticker image “OBSN”. For extra info, please go to  www.ObsEva.com .

About Syneos Well being
Syneos Well being ^®  (Nasdaq:SYNH) is the one totally built-in biopharmaceutical options group. The Firm, together with a Contract Analysis Group (CRO) and Contract Industrial Group (CCO), is purpose-built to speed up buyer efficiency to handle fashionable market realities. We carry collectively roughly 27,000 medical and industrial minds with the flexibility to assist clients in additional than 110 international locations. Collectively we share insights, use the newest applied sciences and apply superior enterprise practices to hurry our clients’ supply of necessary therapies to sufferers. To study extra about how we’re  Shortening the space from lab to life ^® , go to  syneoshealth.com  or  subscribe to our podcast .

Article content material

Cautionary Word Relating to Ahead Trying Statements of ObsEva SA
Any statements contained on this press launch that don’t describe historic details could represent forward-looking statements as that time period is outlined within the Non-public Securities Litigation Reform Act of 1995. These statements could also be recognized by phrases corresponding to “consider”, “count on”, “could”, “plan”, “potential”, “will”, and comparable expressions, and are based mostly on ObsEva’s present beliefs and expectations. These forward-looking statements embrace expectations relating to the medical improvement of and commercialization plans for ObsEva’s product candidates, together with linzagolix, expectations relating to regulatory and improvement milestones, together with the potential timing of regulatory submissions to the EMA and FDA and ObsEva’s capacity to acquire and keep regulatory approvals for its product candidates, and the outcomes of interactions with regulatory authorities, and expectations relating to the usage of funds from the financing settlement with JGB Administration. These statements contain dangers and uncertainties that might trigger precise outcomes to vary materially from these mirrored in such statements. Dangers and uncertainties which will trigger precise outcomes to vary materially embrace uncertainties inherent within the conduct of medical trials and medical improvement, together with the danger that the outcomes of earlier medical trials might not be predictive of the outcomes of later stage medical trials, associated interactions with regulators, ObsEva’s reliance on third events over which it might not at all times have full management, the influence of the continued novel coronavirus outbreak, and different dangers and uncertainties which might be described within the Threat Components part of ObsEva’s Annual Report on Kind 20-F for the 12 months ended December 31, 2020 filed with Securities and Alternate Fee (SEC) on March 5, 2021 and different filings ObsEva makes with the SEC. These paperwork can be found on the Traders web page of ObsEva’s web site at https://www.ObsEva.com. Any forward-looking statements communicate solely as of the date of this press launch and are based mostly on info out there to ObsEva as of the date of this launch, and ObsEva assumes no obligation to, and doesn’t intend to, replace any forward-looking statements, whether or not on account of new info, future occasions or in any other case.

For additional info, please contact:
CEO Workplace contact
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact
Joyce Allaire
jallaire@lifesciadvisors.com
+1 (617) 435-6602

1. Stewart E, ASRM 2020; Late-breaker summary P-930
2. Al-Hendy A, NEJM 2021; 384:630-42
3. Schlaff W, NEJM 2020; 382:328-40
4. Bradley L, ASRM 2020; Late-breaker summary P-931

Attachment